Response, outcomes, CAR expansion, and cytokine levels after CD19.22.BBζ CAR T-cell infusion. (A) Waterfall plot of the best response after CD19.22.BBζ CAR T-cell infusion. Participants were stratified by DL and CRS grade. Bone marrow clearance demonstrates those that were MRD negative by flow cytometry. (B) RFS was calculated from the date of CAR infusion until the date of relapse or last follow-up among those who went into complete remission and was not censored for HSCT. The 6- and 12-month RFS was 80.8% (95% CI: 42.4%-94.9%) and 57.7% (95% CI: 22.1%-81.9%), respectively. (C) OS was calculated from the date of CAR infusion until the date of death or last date of follow-up. The 6- and 12-month OS was 100% and 63.0% (95% CI: 35.4%-81.4%) respectively. (D) Duration of continuous remission among patients who achieved a CR. Shown are duration of remission, time to transplant if applicable, and time of relapse denoted as either antigen negative or antigen positive. (E) Peak CAR T-cell expansion in the PB assessed as absolute CAR T cells based on the percent of absolute lymphocyte count that was CAR T cell positive and stratified by CR vs no CR, and patients who were CAR naïve and CAR pretreated are denoted. (F) Peak percentage of CAR T cells in the bone marrow at day 28 assessment stratified by CR vs no CR, and patients who were CAR naïve and CAR pretreated are denoted. (G-J) Comparison of peak cytokine values of IFNγ, IL18, IL2, and GM-CSF between CR and no CR, with CAR naïve denoted with a red circle and CAR pretreated denoted with a blue triangle.